--- title: KKU-M213 CDX Model - TD2 Precision Oncology description: KKU-M213 stands as a crucial cell line for research on intrahepatic cholangiocarcinoma, enabling deep insights into the disease's biology and offering avenues for therapeutic innovation. image: https://td2inc.com/hubfs/Assets/GraphsFigures/KKU-M213.png --- ×   [![td2-logo](https://td2inc.com/hubfs/td2-logo.png "td2-logo")](https://td2inc.com/?hsLang=en) ![Search Site](https://td2inc.com/hubfs/Assets/Icon/search-icon-1.png) [![td2-logo](https://td2inc.com/hubfs/td2-logo.png "td2-logo")](https://td2inc.com/?hsLang=en) ![Search Site](https://td2inc.com/hubfs/Assets/Icon/search-icon-1.png) # KKU-M213 CDX Model The KKU-M213 cell line is derived from human intrahepatic cholangiocarcinoma (ICC), a rare and aggressive malignancy originating from the bile ducts within the liver. ICC is characterized by its insidious onset and challenging therapeutic management. KKU-M213 provides an indispensable platform for delving into ICC’s complex biology, understanding its pathogenesis, and assessing therapeutic avenues. This cell line embodies the molecular signatures and genetic abnormalities typical of ICC, accentuating its value in preclinical research. The in vitro and in vivo behavior of KKU-M213 sheds light on ICC’s growth kinetics, invasive properties, and potential metastatic tendencies. Researchers utilize the KKU-M213 model to decipher molecular pathways pivotal to ICC progression, to test drug responses, and to pioneer therapeutic strategies targeting ICC’s unique molecular vulnerabilities. ## Model Details **Cancer Location:** Liver **Cancer Type:** Intrahepatic Cholangiocarcinoma **Model Name:** KKU-M213 **Mouse Strain:** NSG **Treatment Data Available:** Chemotherapy (Gemcitabine, Cisplatin) ## KKU-M213 Growth subcurves ![KKU-M213 CDX Model](https://td2inc.com/hubfs/Assets/GraphsFigures/KKU-M213.png) Growth of subcutaneous KKU-M213 in Nu/Nu mice (n=10 mice) ### Request Additional CDX Model Data ## CONTACT US ## Get Started. Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started. [Get Started Now](https://td2inc.com/contact-us/?hsLang=en) [![td2-logo-footer](https://td2inc.com/hs-fs/hubfs/td2-logo.png?width=160&name=td2-logo.png)](https://td2inc.com/?hsLang=en) Office 13208 E. Shea Blvd, Suite 100 Scottsdale, AZ 85259 Phone (602) 358-8300 Connect with us - - ![td2-logo-footer](https://td2inc.com/hs-fs/hubfs/Assets/Logo/acclac-logo.png?width=139&name=acclac-logo.png) © 2026 Translational Drug Development. All Rights Reserved. [Terms and Conditions](https://td2inc.com/terms-and-conditions?hsLang=en) | [Privacy Policy](https://td2inc.com/privacy-policy?hsLang=en)